Recombinant Anti-CD2 x Anti-TCR (Vβ8) Bispecific Antibody (Tandem scFv) is designed to be expressed as a scFv from an anti-CD2 antibody variable domains fused with a scFv from an anti-TCR (Vβ8) antibody variable domains. It contains a His-tag at the C/N terminus for affinity purification. The BsAb exits as monomer in reducing and non-reducing conditions. This BsAb can activate T cells. It is designed for the research of Tumors therapy.